Product logins

Find logins to all Clarivate products below.


Stacey Chang-Douglass

Head of Health Economics and Director in Consulting

Stacey is Head of Health Economics and Director in Consulting at Clarivate.

Stacey has nearly 15 years’ experience in health economics and outcome research at consultancies and at NICE. She specialises in economic modelling to support HTA submissions, global model development and country adaptation and national guidelines across an extensive range of therapeutic areas.

Prior to joining Clarivate, Stacey held senior positions at different consultancies, as Principal Consultant at Parexel, Director in Health Economics at Lumanity and Research Scientist at Evidera, where she led multidisciplinary projects for economic modelling and evidence synthesis. She provided quality assurance for deliverables and technical guidance for the internal team and provided strategic insights to ensure a long-term partnership with the clients.

Stacey serves as a standing committee member at the Medical Technologies Advisory Committee at NICE since 2022. Stacey also serves as a reviewer of funding proposals and HTA reports for NIHR in the UK since 2015.

Stacey holds an MSc in International Health Policy from London School of Economics and a PhD in Health Sciences from the University of York, which focused on outcome measurements in economic evaluations.

Related resources

Multi-product portfolios: addressing complexity through smarter value communication Multi-product portfolios: addressing complexity through smarter value communication
Blog October 9, 2026
Multi-product portfolios: addressing complexity through smarter value communication
Biopharma Commercialization HMO HTA Launch Managed care MCO Payer PBM Pharma pricing
Understanding the impact of drug shortages across markets for API manufacturers Understanding the impact of drug shortages across markets for API manufacturers
Blog October 9, 2026
Understanding the impact of drug shortages across markets for API manufacturers
Biopharma Manufacturing Real-World Data Supply chain
From promise to payment: pricing and reimbursement for combination oncology regimens From promise to payment: pricing and reimbursement for combination oncology regimens
Blog October 9, 2026
From promise to payment: pricing and reimbursement for combination oncology regimens
Biopharma Biotech Bispecific antibodies BsAb Clinical trials Commercialization EMA EMEA Europe HTA Launch Market Access Oncology Payer Pharma Policy pricing
Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
Blog June 24, 2026
Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
ADC Biopharma Biotech Bispecific antibodies BsAb Clinical trials Development Oncology Pharma R&D Regulatory Research